Harald Hartweger

Harald Hartweger

Auto-generated profile, based on publicly available information

Harald Hartweger

Laboratory of Molecular Immunology, The Rockefeller University, New York, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2020 in Nature
Verified
Journal Article
Closed access
PDF file
DRDavide F. Robbiani
Davide F. Robbiani
CGChristian Gaebler
Christian Gaebler
FMFrauke Mücksch
Frauke Mücksch
JLJulio C. C. Lorenzi
Julio C. C. Lorenzi
ZWZijun Wang
Zijun Wang
MNMichel C. Nussenzweig
Michel C. Nussenzweig

1 August 2019 in Immunity
Verified
Journal Article
Closed access
SFShlomo Finkin
Shlomo Finkin
HHHarald Hartweger
Harald Hartweger
TOThiago Y. Oliveira
Thiago Y. Oliveira
EKErvin E. Kara
Ervin E. Kara
MNMichel C. Nussenzweig
Michel C. Nussenzweig

11 April 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
HHHarald Hartweger
Harald Hartweger
AMAndrew T. McGuire
Andrew T. McGuire
MHMarcel Horning
Marcel Horning
JTJustin J. Taylor
Justin J. Taylor
PDPia Dosenovic
Pia Dosenovic
MNMichel C. Nussenzweig
Michel C. Nussenzweig
A small number of HIV-1–infected individuals develop broadly neutralizing antibodies to the virus (bNAbs). These antibodies are protective against infection in animal models. However, they only emerge 1–3 yr after infection, and show a number of highly unusual features including exceedingly high levels of somatic mutations. It is therefore not surprising that elicitation of protective immunity to HIV-1 has not yet been possible. Here we show that mature, primary mouse and human B cells can be edited in vitro using CRISPR/Cas9 to express mature bNAbs from the endogenous Igh locus. Moreover, edited B cells retain the ability to participate in humoral immune responses. Immunization with cognate antigen in wild-type mouse recipients of edited B cells elicits bNAb titers that neutralize HIV-1 at levels associated with protection against infection. This approach enables humoral immune responses that may be difficult to elicit by traditional immunization. Graphical Abstract

16 April 2018 in Proceedings of the National Academy of Sciences of the United States of America
Verified
Journal Article
Closed access
PDF file
PDPia Dosenovic
Pia Dosenovic
EKErvin E. Kara
Ervin E. Kara
APAnna-Klara Pettersson
Anna-Klara Pettersson
AMAndrew T. McGuire
Andrew T. McGuire
MGMatthew Gray
Matthew Gray
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Significance: An essential requirement for an HIV vaccine is to elicit antibodies to conserved regions of the spike protein (i.e., Env) because these antibodies can protect against infection. Although broadly neutralizing antibodies develop naturally in rare individuals after prolonged HIV infection, eliciting them by vaccination has only been possible in artificial knock-in mouse models in which the number of B cells expressing the antibody precursor is superphysiologic. To understand the relationship among precursor frequency, antigen affinity, and germinal center recruitment, we have performed adoptive transfer experiments in which fixed numbers of precursor cells are engrafted in WT mice. Our results provide a framework for an understanding of how precursor frequency and antigen affinity shape humoral immunity to HIV.

19 May 2011 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NGNina Gratz
Nina Gratz
HHHarald Hartweger
Harald Hartweger
UMUlrich Matt
Ulrich Matt
FKFranz Kratochvill
Franz Kratochvill
MJMarton Janos
Marton Janos
PKPavel Kovarik
Pavel Kovarik
Streptococcus pyogenes is a Gram-positive human pathogen that is recognized by yet unknown pattern recognition receptors (PRRs). Engagement of these receptor molecules during infection with S. pyogenes, a largely extracellular bacterium with limited capacity for intracellular survival, causes innate immune cells to produce inflammatory mediators such as TNF, but also type I interferon (IFN). Here we show that signaling elicited by type I IFNs is required for successful defense of mice against lethal subcutaneous cellulitis caused by S. pyogenes. Type I IFN signaling was accompanied with reduced neutrophil recruitment to the site of infection. Mechanistic analysis revealed that macrophages and conventional dendritic cells (cDCs) employ different signaling pathways leading to IFN-beta production. Macrophages required IRF3, STING, TBK1 and partially MyD88, whereas in cDCs the IFN-beta production was fully dependent on IRF5 and MyD88. Furthermore, IFN-beta production by macrophages was dependent on the endosomal delivery of streptococcal DNA, while in cDCs streptococcal RNA was identified as the IFN-beta inducer. Despite a role of MyD88 in both cell types, the known IFN-inducing TLRs were individually not required for generation of the IFN-beta response. These results demonstrate that the innate immune system employs several strategies to efficiently recognize S. pyogenes, a pathogenic bacterium that succeeded in avoiding recognition by the standard arsenal of TLRs. Streptococcus pyogenes is an important human pathogen that causes a broad range of diseases. The bacterium colonizes the throat and the skin where it can evoke usually mild illness such as strep throat or scarlet fever. Systemic infections with S. pyogenes are less frequent but can develop into life-threatening diseases such as necrotizing fasciitis and streptococcal toxic shock syndrome. The immune system launches a usually successful response that is initiated by a so far not understood recognition of this pathogen by the cells of the innate immune system. These cells produce upon infection a variety of cytokines that orchestrate a full blown protective response. Among these cytokines, type I interferons play a critical role as demonstrated by our study. We further show that IFN-beta, the key type I interferon, is produced only after macrophages and dendritic cells have taken up the pathogen and liberated the bacterial nucleic acids for recognition in the intracellular vesicles. Importantly, macrophages and dendritic cells recognize different nucleic acids and employ different signaling pathways to respond. Our data suggest that the innate immune system employs several strategies to efficiently recognize S. pyogenes, a pathogenic bacterium that succeeded in avoiding recognition by the standard recognition mechanisms.

28 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
CBChristopher O. Barnes
Christopher O. Barnes
HGHarry B. Gristick
Harry B. Gristick
NFNatalia T. Freund
Natalia T. Freund
AEAmelia Escolano
Amelia Escolano
ALArtem Y. Lyubimov
Artem Y. Lyubimov
Pamela J BjorkmanPamela J Bjorkman
Pamela J Bjorkman
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccine design efforts. Developing bNAbs with increased efficacy requires understanding how antibodies interact with the native oligomannose and complex-type N-glycan shield that hides most protein epitopes on HIV-1 envelope (Env). Here we present crystal structures, including a 3.8-Å X-ray free electron laser dataset, of natively glycosylated Env trimers complexed with BG18, the most potent V3/N332gp120 glycan-targeting bNAb reported to date. Our structures show conserved contacts mediated by common D gene-encoded residues with the N332gp120 glycan and the gp120 GDIR peptide motif, but a distinct Env-binding orientation relative to PGT121/10-1074 bNAbs. BG18’s binding orientation provides additional contacts with N392gp120 and N386gp120 glycans near the V3-loop base and engages protein components of the V1-loop. The BG18-natively-glycosylated Env structures facilitate understanding of bNAb–glycan interactions critical for using V3/N332gp120 bNAbs therapeutically and targeting their epitope for immunogen design.